-
Mayo Clinic research uses artificial intelligence to develop inexpensive, widely available early detector of silent heart disease
Share this:
ROCHESTER, Minn. — A Mayo Clinic study finds that applying artificial intelligence (AI) to a widely available, inexpensive test – the electrocardiogram (EKG) – results in a simple, affordable early indicator of asymptomatic left ventricular dysfunction, which is a precursor to heart failure. The research team found that the AI/EKG test accuracy compares favorably with other common screening tests, such as mammography for breast cancer. The findings were published in Nature Medicine.
Asymptomatic left ventricular dysfunction is characterized by the presence of a weak heart pump with a risk of overt heart failure. It affects 7 million Americans, and is associated with reduced quality of life and longevity. But asymptomatic left ventricular dysfunction is treatable when identified.
However, there is no inexpensive, noninvasive, painless screening tool for asymptomatic left ventricular dysfunction available for diagnostic use. The Mayo study reports that the best existing screening test for asymptomatic left ventricular dysfunction is to measure natriuretic peptide levels (BNP), but results of BNP have been disappointing. And the test requires blood draws. Left ventricular dysfunction typically is diagnosed with expensive and less accessible imaging tests, such as echocardiograms, or CT or MRI scans.
“Congestive heart failure afflicts more than 5 million people and consumes more than $30 billion in health care expenditures in the U.S. alone,” says Paul Friedman, M.D., senior author and chair of the Midwest Department of Cardiovascular Medicine at Mayo Clinic. "The ability to acquire an ubiquitous, easily accessible, inexpensive recording in 10 seconds – the EKG – and to digitally process it with AI to extract new information about previously hidden heart disease holds great promise for saving lives and improving health," he says.
In their study, Mayo Clinic researchers hypothesized that asymptomatic left ventricular dysfunction could be reliably detected in the EKG by a properly trained neural network. Using Mayo Clinic stored digital data, 625,326 paired EKG and transthoracic echocardiograms were screened to identify the population to be studied for analysis. To test their hypothesis, researchers created, trained, validated and then tested a neural network.
The study concluded that AI applied to a standard EKG reliably detects asymptomatic left ventricular dysfunction. The accuracy of the AI/EKG test compares favorably with other common screening tests, such as prostate-specific antigen for prostate cancer, mammography for breast cancer and cervical cytology for cervical cancer.
In addition, in patients without ventricular dysfunction, those with a positive AI screen were at four times the risk of developing future ventricular dysfunction, compared with those with a negative screen. “In other words, the test not only identified asymptomatic disease, but also predicted risk of future disease, presumably by identifying very early, subtle EKG changes that occur before heart muscle weakness,” notes Dr. Friedman.
Study co-authors are: Zachi Attia; Suraj Kapa, M.D.; Francisco Lopez-Jimenez, M.D.; Paul McKie, M.D.; Dorothy Ladewig; Gaurav Satam; Patricia Pellikka, M.D.; Maurice Enriquez-Sarano, M.D.; Peter Noseworthy, M.D.; Thomas Munger, M.D.; Samuel Asirvatham, M.D.; Christopher Scott; and Rickey Carter, Ph.D., all of Mayo Clinic.
This research was made possible in part by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.
###
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, comprehensive care to everyone who needs healing. Learn more about Mayo Clinic. Visit the Mayo Clinic News Network.
Media contact:
- Traci Klein, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu
